参松养心胶囊治疗心房颤动的系统评价再评价  

Shensong Yangxin Capsule Therapy for Atrial Fibrillation:an Overview of Systematic Reviews

作　　者：任星 杨静[1,2] 张菀桐 高蕊 REN Xing;YANG Jing;ZHANG Wantong;GAO Rui(Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China)

机构地区：[1]中国中医科学院西苑医院,北京100091 [2]北京中医药大学研究生院

出　　处：《中西医结合心脑血管病杂志》2021年第22期3830-3834,共5页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

基　　金：国家重点研发计划“中医药现代化研究”基金资助项目(No.2019YFC1709300)。

摘　　要：目的对目前已发表的参松养心胶囊治疗心房颤动的系统评价/Meta分析进行再评价。方法计算机检索PubMed、the Cochrane Library、EMbase、中国知网(CNKI)、维普(VIP)、万方数据库(Wanfang Data)、中国生物医学文献数据库(CBM),搜集参松养心胶囊治疗心房颤动的系统评价/Meta分析,检索时限为建库至2020年5月。由2名研究者独立筛选文献及提取资料,并交叉核对。采用AMSTAR 2量表评价纳入研究的方法学质量,应用PRISMA声明进行报告质量评估。结果最终纳入6篇系统评价/Meta分析。AMSTAR 2量表方法学质量评价整体偏低,6篇均为极低质量,关键条目2、7、13、15及非关键条目3、10、12、14、16方面的方法学质量存在较大缺陷。PRISMA清单得分范围为14.0~21.5分,存在的报告质量问题主要表现在方案注册、资料提取、单个研究存在的偏倚、研究内部的偏倚以及资金来源、利益冲突等方面。结论现有研究表明参松养心胶囊治疗心房颤动的系统评价/Meta分析方法学质量极低,报告质量存在严重缺陷,应严格规范质量以期获得更高质量的临床证据。Objective To overview the systematic reviews/Meta analysis of Shensong Yangxin Capsule in the treatment of atrial fibrillation.Methods PubMed,the Cochrane Library,EMbase,CNKI,VIP,Wanfang Data,and CBM were searched by computer to collect the systematic review/Meta analysis of Shensong Yangxin Capsule in the treatment of atrial fibrillation form inception to May 2020.The literature and extracted data were independently screened and cross-checked by two researchers.AMSTAR 2 scale was used to evaluate the methodological quality of the study,and PRISMA statement was used to evaluate the quality of the report.Results Finally,6 systematic reviews/Meta analysis were included.The methodological quality evaluation of AMSTAR 2 scale was poor as a whole,6 articles were of very poor quality,and there were great defects in the methodological quality of key items 2,7,13,15 and non-key items 3,10,12,14,and 16.The score range of PRISMA inventory was 14.0~21.5.The problems in reporting quality were mainly manifested in scheme registration,data extraction,bias in individual studies,internal bias in research,funding sources,conflicts of interest and so on.Conclusion At present,the quality of systematic review/Meta analysis methodology of Shensong Yangxin Capsule in the treatment of atrial fibrillation is very poor,and there are serious defects in the quality of the report,so the quality should be strictly regulated in order to obtain higher quality clinical evidence.

关 键 词：心房颤动 参松养心胶囊 系统评价再评价 

分 类 号：R54[医药卫生—心血管疾病]